USFDA Clears Dr. Reddy’s Facility

  Published 1 year ago

Dr. Reddy’s facility inspection by the USFDA closes with VAI status; the company is committed to addressing all inspection observations.

  • USFDA issued an Establishment Inspection Report (EIR) post-GMP audit; inspection formally closed under regulatory guidelines.
  • Two observations cited in the May 2025 inspection, Dr. Reddy’s, are to be resolved within the required timeline.
  • Q4FY25 profit rose 22% YoY to ₹1,594 crore; revenue up 20% at ₹8,506 crore; stock down 0.44%.

You might like these

Kotak Mahindra Bank Hits 2‑Month High

Prucalopride vs. Motegrity: CIC Market Insights

Adani Denies U.S. Bribery Allegations Affirms Clean Record

OneSource Pharma Eyes Obesity Drug Growth, Expansion

Oracle Partners with AI Innovators to Boost Cloud AI

Prince Pipes FY25: Mixed Results & Future Outlook

Mahindra EPC Irrigation Q2 Highlights

News that matters the most ⚡